🟢 Regeneron Pharmaceuticals is trading 4.3% up today after Q3 earnings beat estimates

Regeneron Pharmaceuticals is trading at $967.45 (+4.26%) after its October 30 results beat estimates.

• Revenue rose 36% to $5.1 billion, while non-GAAP EPS reached $20.07.
• Sanofi collaboration revenue climbed 68%, and analysts raised price targets after the results, adding company-specific support for the move.
• Broader markets are also higher; no current intraday volume was provided.